RESUMEN
Player movement is a fundamental component of evaluating performance in most team sports. Movement can be evaluated across multiple scales, referring to the function of anatomical structures through various planes of motion or an individual regulating their field position based on the movement of opposition players. Developments in commercially available tracking systems have afforded end users the ability to investigate the spatiotemporal features of movement in fine detail. These advancements, in conjunction with overlaid contextual information, have provided insights into the strategies adopted by players in relation to their movement. Understanding movement beyond its semantic value allows practitioners to make informed decisions surrounding performance evaluation and training design. This investigation proposes a framework to guide the analysis of player movement within team sports environments. The framework describes how operational standards for assessing movement can be designed in reference to theory and a set training philosophy. Such practice allows for the spatial and temporal complexities within team sports to be described and could potentially lead to better-applied outcomes through greater interdisciplinary collaboration and an improved holistic understanding of movement. To inform its development, this study evaluates the current research and identifies several open questions to guide future investigations.
RESUMEN
UNLABELLED: Because of the presence of cell membrane somatostatin receptors (SSTRs), many neuroendocrine tumors will bind analogs of somatostatin. (90)Y-Dodecanetetraacetic acid-Phe1-Tyr3-octreotide (SMT 487) is an SSTR radiopharmaceutical currently under investigation as a therapeutic option for neuroendocrine tumors. Although there are a variety of methods for evaluating response to a given cancer therapy, an important indicator of success is the impact on the clinical status of the patient. The purpose of this work was to develop a semiquantitative method and assess the clinical effectiveness of (90)Y-SMT 487 therapy in patients with neuroendocrine tumors. METHODS: A scoring system was developed to evaluate clinical response that included the following parameters: weight, health status score (determined by the patient), Karnofsky score, and tumor-related symptoms. RESULTS: We applied this scoring system to 21 patients who had completed 3 cycles of therapy with (90)Y-SMT 487. Fourteen of the 21 showed a favorable clinical response, whereas 5 were clinically stable after treatment and 2 showed evidence of clinical progression. There was also a significant reduction in the amount of octreotide being used after completion of (90)Y-SMT 487 therapy in the 20 patients who were on this medication. CONCLUSION: Using this scoring method, (90)Y-SMT 487 appears effective in improving the clinical status of patients with (111)In-pentetreotide-positive neuroendocrine tumors.
Asunto(s)
Tumores Neuroendocrinos/radioterapia , Octreótido/análogos & derivados , Octreótido/administración & dosificación , Radioisótopos de Itrio/administración & dosificación , Adulto , Anciano , Relación Dosis-Respuesta en la Radiación , Femenino , Humanos , Inyecciones Intravenosas , Masculino , Persona de Mediana Edad , Tumores Neuroendocrinos/diagnóstico , Tumores Neuroendocrinos/diagnóstico por imagen , Tumores Neuroendocrinos/secundario , Calidad de Vida , Radiografía , Radiofármacos/administración & dosificación , Dosificación Radioterapéutica , Resultado del TratamientoRESUMEN
The purpose of this study was to determine whether there is evidence for hepatocellular radiation injury following treatment with (90)Y-SMT487 ((90)Y-DOTA-tyr3-octreotide, OctreoTher(TM)) in patients with extensive liver metastases from neuroendocrine tumors. Patients reported in this study participated in a Phase II trial of efficacy and safety of (90)Y-SMT487. The trial design called for three treatment cycles of 120 mCi each (4400 MBq) of (90)Y-SMT487. (111)In-pentetreotide SPECT images were used to determine the extent of liver metastases. Serum AST, ALT, and alkaline phosphatase levels were obtained at baseline and following each cycle of therapy. Least squares fit was applied to the serial liver enzyme measurements in patients with extensive liver metastases. Post-therapy liver enzyme measurements were also evaluated using WHO common toxicity criteria. Repeated-measures ANOVA and paired t-test were applied to the serial enzyme measures. There were 21 subjects. Fifteen of these had hepatic metastases with 12 demonstrating extensive (defined as 25% or more) liver involvement. In only 4 of these 15 did any of the three enzyme levels increase in WHO toxicity grade from baseline to final follow-up. We conclude that patients with diffuse SSTR positive hepatic metastases can be treated with a cumulative administered activity of 360 mCi (90)Y-SMT487 with only a small chance of developing mild acute or subacute hepatic radiation injury.